Headquartered in Novato, CA·Fiscal year ends December·NASDAQ: RARE·ultragenyx.com
About Ultragenyx
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical company that develops and commercializes novel therapies for serious rare and ultra-rare genetic diseases with high unmet medical need and clear biology.
Its commercial portfolio includes:
- CRYSVITA (burosumab) for X-linked hypophosphatemia. Kyowa Kirin commercializes it in the U.S., Canada and Europe, paying royalties to Ultragenyx, while Ultragenyx records product sales in Latin America and Türkiye.
- DOJOLVI.
- EVKEEZA.
- MEPSEVII.
- Two newly FDA-approved AAV gene therapies: GENGLYCOS for glycogen storage disease type Ia (accelerated approval, August 2026) and FAYUVI for Sanfilippo syndrome type A (full approval, September 2026).
Revenue comes from product sales and royalties.
After completing its late-stage programs, the company is restructuring toward commercial execution and a smaller R&D footprint. It is cutting headcount by about 20% to roughly 1,000 employees and ending the GTX-102 and UX701 programs. Its remaining pipeline focus is DTX301 for OTC deficiency, UX143 (setrusumab) for osteogenesis imperfecta, UX016 for GNE myopathy, and early-stage programs. Updated
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names…
Pre-Market Stock Futures: After a volatile start to the week, futures are trading lower on Tuesday. Markets had plummeted early Monday before the opening bell, only to stage a massive turnaround following…
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Apple, AT&T, Cenovus Energy, Dollar General, Dynatrace, FedEx, Molson Coors Beverage, NiSource, Uber Technologies and Vale.
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's, Microsoft, PulteGroup and Tesla.
Friday's top analyst upgrades and downgrades included AMC Entertainment, CNH Industrial, Kala Pharmaceuticals, Opendoor Technologies, Tesla and TG Therapeutics.
Friday's top analyst upgrades and downgrades included Altice USA, Apple, Colgate-Palmolive, Marathon Petroleum, Mastercard, Medtronic, Meta Platforms, Nike, Prologis, Realty Income, SLM, Tenaris and Visa.
Tuesday's top analyst upgrades and downgrades included Canopy Growth, Constellation Brands, Equifax, FedEx, Franklin Resources, Micron Technology, Paramount Global, RH and T-Mobile.
Wednesday afternoon's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Constellation Energy, Edwards Lifesciences, Host Hotels & Resorts, Johnson & Johnson and Magna International.
Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these inexpensive…
Tuesday’s top analyst upgrades and downgrades included Coursera, CSX, Carvana, FedEx, Fox, Marathon, Petro China, Planet Fitness, Regeneron and Rackspace.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical company that develops and commercializes novel therapies for serious rare and ultra-rare genetic diseases with high unmet medical need and clear biology. Its commercial portfolio includes: - CRYSVITA (burosumab) for X-linked hypophosphatemia.
What is the RARE stock price target?
24/7 Wall St.'s 12-month price target for RARE is $29.56, rated Buy. The Wall Street consensus target is $24.80. RARE price prediction →